NEUROENDOCRINE TUMORS

This study tests whether combining two drugs—atezolizumab (an immunotherapy) and tivozanib (a targeted therapy)—can shrink tumors in cancers that typically don't respond to immunotherapy alone. About 29 adults with advanced bile duct, gallbladder, breast, neuroendocrine, ovarian,…

This early-phase study tests a new combination of two treatments—cabozantinib (a targeted drug) and radioactive Lu-177 DOTATATE—for people with advanced neuroendocrine tumors that have stopped responding to standard therapy. The main goal is to find the safest dose of cabozantini…

This study tests two drugs, pembrolizumab and lenvatinib, in 45 people with advanced neuroendocrine prostate cancer that has spread. The goal is to see if the combination can slow tumor growth. Treatment continues until the cancer worsens or side effects become too severe, for up…

This early-phase study tests if giving the drug Lutathera directly into the liver's main artery is safe and practical for people with neuroendocrine tumors that have spread mostly to the liver. Ten participants will receive two infusions, one into the liver artery and one into a …

This study tests a new treatment for people with advanced high-grade neuroendocrine tumors (a rare and fast-growing cancer). The treatment combines chemotherapy (etoposide and carboplatin) with an immunotherapy drug (pembrolizumab), followed by maintenance therapy with pembrolizu…

This study tests whether the immunotherapy drug avelumab can help prevent Merkel cell carcinoma from coming back after initial treatment. About 122 people with stage I to III Merkel cell carcinoma are randomly assigned to receive either avelumab or a placebo. The main goal is to …

This study tests an experimental drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking signals that help it grow. About 534 adults with various cancers, including…

This study tests a new radioactive drug, 212Pb-DOTAMTATE, in 69 adults with neuroendocrine tumors that have spread or cannot be removed. The drug targets tumor cells and delivers radiation directly to them. The goal is to see if it shrinks tumors and to check for side effects. Pa…

This study tests a new type of radiation therapy (PRRT with 177Lu-Edotreotide) against a standard targeted drug (everolimus) in 324 people with advanced neuroendocrine tumors of the gut or pancreas that can't be removed by surgery. The goal is to see which treatment better delays…

This phase 3 study tested a radioactive drug called Lutetium-177 oxodotreotide against a high dose of the standard drug octreotide in 196 people with advanced neuroendocrine tumors (NETs) that could not be removed by surgery. The goal was to see which treatment better delayed tum…

This study tests whether combining two immunotherapy drugs, ipilimumab and nivolumab, can shrink or control rare cancers that have not responded to other treatments. The trial includes 240 adults with advanced biliary tract, neuroendocrine, gynecologic, or MSI-H solid tumors. Res…

This study looks at the long-term safety of Lutathera, a treatment for advanced neuroendocrine tumors that cannot be removed by surgery or have spread. Over 1,000 adults who have already received Lutathera are being followed to track any new cancers, side effects, and overall sur…

This study tests an experimental oral drug called CVM-1118 in 34 people with advanced neuroendocrine tumors that have not responded to standard treatments. The goal is to see if the drug can slow tumor growth or shrink tumors. Participants take the drug by mouth and are monitored…

This early-phase study tests a new radioactive drug called [212Pb] VMT-alpha-NET in 24 adults with advanced neuroendocrine tumors that have stopped responding to other treatments. The main goal is to find a safe dose for future studies, not to provide a cure or direct benefit. Pa…

This study compares a targeted radiation treatment (PRRT with 177Lu-Edotreotide) to the best standard care for people with aggressive neuroendocrine tumors of the gut or pancreas. About 259 adults with tumors that have specific markers (SSTR+) will be enrolled. The goal is to see…

This study tests a treatment called Lu-DOTATATE, which delivers radiation directly to neuroendocrine tumor cells. About 195 people with tumors that have a specific marker (somatostatin receptors) will receive up to 4 cycles of this therapy, with doses adjusted for each person. Th…

This study tests a combination of two drugs—nivolumab (an immunotherapy that helps the immune system attack cancer) and temozolomide (a chemotherapy that kills cancer cells)—in people with advanced small-cell lung cancer or neuroendocrine tumors that have come back or stopped res…

This study is testing a new type of PET/CT scan that uses a special tracer (68Ga-DOTATOC) to find neuroendocrine tumors and other related cancers. The goal is to see if this scan is safer and more sensitive than current imaging methods. About 800 people with known or suspected tu…

This study looks at whether adding a second type of PET scan (FDG) to the standard scan (DOTATATE) gives doctors more information about neuroendocrine tumors. About 40 adults with grade 2 or 3 gastroenteropancreatic neuroendocrine tumors will get both scans. The goal is to see if…

This study follows over 2500 adults with neuroendocrine tumors (NETs) to learn how symptoms affect their lives and how doctors choose treatments. Participants fill out surveys about quality of life and care experiences over 18 months. The goal is to find the best ways to sequence…

This study tests whether a new total-body PET scanner can improve cancer imaging for people with prostate cancer, breast cancer, or neuroendocrine tumors. Nine participants will receive one of three FDA-approved imaging agents to see how well the scanner captures tumor activity. …

This study looks at 500 people with advanced neuroendocrine tumors to see which order of two treatments works best: starting with surufatinib then somatostatin analogs, or the reverse. Researchers will track how long the cancer stays under control and any side effects. The goal i…

This study compares three different PET/CT scans (68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG) in 50 people with metastatic neuroendocrine tumors. The goal is to see if the scans agree or disagree on which tumors are present, and whether differences relate to disease progression. Par…

This study is testing new guidelines for reading PET scans in people with neuroendocrine tumors. The goal is to see if these new criteria can more accurately predict whether a person's cancer improves, worsens, or stays the same after treatment. About 11 participants who are alre…

This study does not provide new treatment. Instead, it follows up to 1,150 people who previously received experimental cell or gene therapies for cancers like melanoma and neuroendocrine tumors. Participants will have yearly physical exams and blood tests for up to 15 years to mo…